Loading stock…

MSCI Inc. (MSCI) Stock Verdict & Ratings | Investment Bastion

02Growth

Is it actually growing, and how fast?

MSCIMSCI

Revenue FY25$3.1B

GROWTH RATING↗

STRONG69 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+12%7

Revenue, next 1Y+12%7

Revenue, next 3Y, CAGR+10%7

Revenue, next 5Y, CAGR+9%7

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+25%8

EPS growth, FY27E+13%7

EPS growth, FY28E+11%7

GROWTH ASSESSMENT

STRENGTHS

It out-grows 69% of companies worldwide.

Revenue grew 12%/yr over the last 3 years, ahead of 60% of companies worldwide.7/10

Revenue is set to grow 10%/yr over the next 3 years, ahead of most of the market.7/10

Revenue grew 12%/yr over the last 3 years and is set to keep growing around 10%/yr.

The runway holds up: revenue is set to grow 9%/yr over five years.7/10

Earnings are set to grow in step with sales (EPS about 13%/yr vs revenue 10%/yr).

WATCH

None flagged.

WEAKNESSES

None flagged.

BOTTOM LINE

Elite Compounder

A top-tier grower.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

WEAK33 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-3%6

3-month return-8%4

YTD return-2%4

MID & LONG-TERM▾SCORE

% of 52-week high86%7

1-year return-1%4

3-year return+12%3

5-year return-3%3

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

It's down 1% over the past year, now 14% below its 52-week high. That is a touch ahead of the market.

Returns sit at the market level over the past month (-3%), over three months (-8%) and so far this year (-2%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (+12% over three years and -3.4% over five), behind 70% of the market.

BOTTOM LINE

Falling Knife

Returns rank poorly over both the short and long run, and the price is still falling. Momentum is firmly negative — catching this is a bet against the tape, not with it. Wait for a base to form. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on MSCI. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

MSCIMSCI

Revenue FY25$3.1B

GROWTH RATING↗

STRONG69 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+12%7

Revenue, next 1Y+12%7

Revenue, next 3Y, CAGR+10%7

Revenue, next 5Y, CAGR+9%7

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+25%8

EPS growth, FY27E+13%7

EPS growth, FY28E+11%7

GROWTH ASSESSMENT

STRENGTHS

It out-grows 69% of companies worldwide.

Revenue grew 12%/yr over the last 3 years, ahead of 60% of companies worldwide.7/10

Revenue is set to grow 10%/yr over the next 3 years, ahead of most of the market.7/10

Revenue grew 12%/yr over the last 3 years and is set to keep growing around 10%/yr.

The runway holds up: revenue is set to grow 9%/yr over five years.7/10

Earnings are set to grow in step with sales (EPS about 13%/yr vs revenue 10%/yr).

WATCH

None flagged.

WEAKNESSES

None flagged.

BOTTOM LINE

Elite Compounder

A top-tier grower.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

WEAK33 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-3%6

3-month return-8%4

YTD return-2%4

MID & LONG-TERM▾SCORE

% of 52-week high86%7

1-year return-1%4

3-year return+12%3

5-year return-3%3

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

It's down 1% over the past year, now 14% below its 52-week high. That is a touch ahead of the market.

Returns sit at the market level over the past month (-3%), over three months (-8%) and so far this year (-2%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (+12% over three years and -3.4% over five), behind 70% of the market.

BOTTOM LINE

Falling Knife

04Value

Are you paying a fair price for it?

Stop guessing on MSCI. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

MSCI Inc.

01Key Ratings

02Growth

03Price Momentum

04Value

Stop guessing on MSCI. Get the full investment case.

Premium

02Growth

03Price Momentum

04Value

Stop guessing on MSCI. Get the full investment case.

Premium